Issues
-
Cover Image
Cover Image
About the Cover
Depending on the type of signals encountered, a resting dendritic cell is converted into either a tolerogenic or an immunogenic state that programs the development of subsets of T cells, each with distinct functions adapted to the signal detected by the dendritic cell. Different arrays of cytokines released by these differentially matured dendritic cells play an important role in determining T-cell development outcomes. The cover image is a schematic diagram of the functional consequences of dendritic cell maturation. For details see the Masters of Immunology article by Ira Mellman on page 145 of this issue. [The cover image was rendered by Allison Bruce (Genentech).]
About the Master
Ira Mellman received his AB degree from Oberlin College and his PhD degree in genetics from Yale University School of Medicine. He was a postdoctoral fellow and later assistant professor at The Rockefeller University, working with the late Ralph M. Steinman, the 2011 Nobel Prize winner in Physiology or Medicine. Dr. Mellman joined the Yale Department of Cell Biology, which was then headed by Nobel Laureate Dr. George E. Palade, whom he eventually succeeded as chair. Dr. Mellman has been a long-time member of the Ludwig Institute for Cancer Research and served as Scientific Director of the Yale Comprehensive Cancer Center. He is a member of the U.S. National Academy of Sciences, a fellow of the American Academy of Arts and Sciences, and an elected foreign member of the European Molecular Biology Organization. Dr. Mellman is the founder of CGI Pharmaceuticals, Inc. (now owned by Gilead) and Athersys, Inc., and an advisor to research institutes and foundations around the world.
Dr. Mellman's work has contributed numerous fundamental concepts to our current understanding of cell biology and immunology, beginning with the discovery, definition, and naming of a “new” organelle, the endosome. Extending this work, his laboratory helped to elucidate the mechanisms by which epithelial cells polarize to form tissues and initiate cancer and revealed the various specializations responsible for the ability of dendritic cells to initiate immune responses.
Dr. Mellman joined Genentech in 2007 as the Vice President of Research Oncology. Placed in charge of the largest therapeutic area in Genentech's research organization, Dr. Mellman is responsible for leading all aspects of oncology research and advancing both antibody and small-molecule drug candidates into the clinic. The development of immunotherapeutic approaches to cancer is now a key feature of Genentech's activities. Dr. Mellman also serves as Professor of Biochemistry and Biophysics at the University of California, San Francisco. - PDF Icon PDF LinkTable of Contents
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
Masters of Immunology
Cancer Immunology at the Crossroads: Microbiology
Cancer Immunology Miniatures
Priority Brief
Research Articles
Chemoimmunotherapy Using Pegylated Liposomal Doxorubicin and Interleukin-18 in Recurrent Ovarian Cancer: A Phase I Dose-Escalation Study
Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.